Matthew Peters

Jun 22, 2024 | onlinelibrary.wiley.com | Eve Denton |Mark Hew |Matthew Peters |John W. Upham

1 INTRODUCTION Targeted monoclonal antibodies for patients with severe asthma and type 2-high inflammation have been shown to decrease exacerbations, reduce symptoms, improve lung function, and enhance quality of life.1-9 Anti-interleukin (IL) 5/IL5 receptor (anti-IL5/IL5R) and anti-IL4/13, and, more recently, anti-immunoglobulin E (anti-IgE) agents have also been shown to reduce the long-term oral corticosteroids (LTOCS) burden.1, 5, 10, 11 However, because only a minority of patients with...